New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.

Autor: Bortoluzzi P; Postgraduate School of Dermatology and Venereology, Università degli Studi, Milan, Italy., Ferrucci S; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Galimberti D; Department of Ophthalmology, Università degli Studi, IRCCS Foundation, Cà Granda Ospedale Maggiore Policlinico, Milan, Italy., Garavelli F; Postgraduate School of Ophthalmology, Università degli Studi, Milan, Italy., Pozzo Giuffrida F; Postgraduate School of Ophthalmology, Università degli Studi, Milan, Italy., Pizzati A; Postgraduate School of Dermatology and Venereology, Università degli Studi, Milan, Italy., Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Mapelli C; Department of Ophthalmology, Università degli Studi, IRCCS Foundation, Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
Jazyk: angličtina
Zdroj: The British journal of dermatology [Br J Dermatol] 2022 Jan; Vol. 186 (1), pp. 186-187. Date of Electronic Publication: 2021 Sep 30.
DOI: 10.1111/bjd.20706
Abstrakt: Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.
(© 2021 British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz: